The EC’s approval was based on results from the phase 3 OASIS-HAE study. The study showed that an 80mg dose of Dawnzera every ...

Ionis IONS and its Japanese partner, Otsuka Pharmaceutical, announced that the European Commission has approved Dawnzera (donidalorsen) for the prevention of recurrent attacks of hereditary angioedema ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European ...

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases ...

Please provide your email address to receive an email when new articles are posted on . Sebetralstat is FDA-approved in patients aged 12 years and older with hereditary angioedema. In children, the ...

Otsuka Pharmaceutical, which licensed the antisense oligonucleotide from Ionis, has rights to commercialize it in Europe and Asia.

Otsuka’s Dawnzera is now approved in the EU to prevent hereditary angioedema attacks in patients 12 and older, offering a ...

Like angioedema in general, hereditary angioedema (HAE) is characterized by subcutaneous or submucosal edema that is nonpruritic — ie, does not itch — and nonpitting — ie, does not leave an ...

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001) All secondary efficacy endpoints met (p<0.0001), including End of ...